Cravatex Limited (509472) Fair Value & Analysis
Other · IN · Market cap ₹704M
Fair value as of: Jul 4, 2026
From 17 valuation models · updated today
Share price +12.9% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹305.20 – ₹515.80 · fair‑value band ₹335.34 – ₹443.67 · the ₹396.95 price screens above the ₹363.65 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Cravatex Limited (509472) currently trades at ₹396.95, while our model-based Fair Value estimate is ₹363.65 — implying the stock looks roughly 8.4% overvalued today. We read business quality at 59/100 (solid quality), in the Other sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Cravatex Limited generated revenue of ₹6.7B at a net margin of -1.7%. Revenue declined 67.2% year over year. Net debt stands at ₹1.3B. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Cravatex Limited, through its subsidiaries, deals in consumer brands, sports goods, and fitness equipment business in India, the United Kingdom, Ireland, Europe, the Middle East, the United States, Nepal, Sri lanka etc. The company operates through Sports and Wellness segments. It is involved in trading footwear, apparel, gym equipment, and related accessories; and the retail sale of fitness equipment. In addition, the company engages in designing, sourcing, and marketing branded apparel and footwear as a licensee for the Fila brand. Cravatex Limited was incorporated in 1951 and is headquartered in Mumbai, India. Cravatex Limited is a subsidiary of R.B. Fitness and Trading Private Limited.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Cravatex Limited reported revenue of ₹1.5B in FY2026 versus ₹5.9B in FY2022, a compound −29.0%/yr. Reported net income was ₹68.0M in FY2026.
Is 509472 fairly valued? → Check now
Similar stocks
6 more Other stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| There MOH | €521.90 | €269.92 | -48% |
| Sony Corporation SON1 | €17.58 | €37.56 | +114% |
| Federal Home Loan Mortgage Corporation FREJO | $16.84 | $64.93 | +286% |
| 533278 533278 | ₹438.60 | ₹720.31 | +64% |
| Nestl?? India Limited 500790 | ₹1,459 | ₹279.60 | -81% |
| 540376 540376 | ₹3,993 | ₹1,806 | -55% |
Explore undervalued stocks
Frequently asked questions
Is Cravatex Limited (509472) undervalued?
What is the fair value of 509472?
What is the quality score of 509472?
What is the revenue of Cravatex Limited (509472)?
What is the net profit margin of 509472?
Does Cravatex Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.